Advertisement
Singapore markets closed

  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • Dow

    38,852.27
    +176.59 (+0.46%)
     

  • Nasdaq

    16,349.25
    +192.92 (+1.19%)
     

  • Bitcoin USD

    63,520.13
    -768.48 (-1.20%)
     

  • CMC Crypto 200

    1,315.58
    -49.54 (-3.63%)
     

  • FTSE 100

    8,298.23
    +84.74 (+1.03%)
     

  • Gold

    2,321.30
    -9.90 (-0.42%)
     

  • Crude Oil

    78.30
    -0.18 (-0.23%)
     

  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     

  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     

  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     

  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     

  • Jakarta Composite Index

    7,123.61
    -12.28 (-0.17%)
     

  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

Genmab's Darzalex could achieve peak annual sales of $9 billion - CEO

Reuters
Genmab Chief Executive Jan van de Winkel poses for a photograph in London, Britain, October 13, 2016. REUTERS/Ben Hirschler

COPENHAGEN (Reuters) - Danish biotech drugmaker Genmab's (GEN.CO) Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson (JNJ.N), has the potential to achieve annual peak annual sales as high as $13 billion (10.46 billion pounds), its chief executive told Reuters.

"It could work in other blood cancers as well as in solid tumours. So that means $13 billion potential if it would work in all the indications, Jan van de Winkel said on Wednesday.

He acknowledged that $13 billion would be the most rosy scenario but said that Darzalex could "definitely" achieve more than $9 billion.

Genmab expects sales of Darzalex to surpass $1 billion this year, the company said on Wednesday.

(Reporting by Stine Jacobsen; Editing by David Goodman)